Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Prospective Single Arm Phase II Study Evaluating Efficacy & Safety of Durvalumab With Carboplatin/Paclitaxel as First Line Treatment in Patients With Recurrent/Metastatic SCCHN Not Eligible to Standard Chemotherapy

NCT03723967 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT03723967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03723967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Prospective Single Arm Phase II Study Evaluating Efficacy & Safety of Durvalumab With Carboplatin/Paclitaxel as First Line Treatment in Patients With Recurrent/Metastatic SCCHN Not Eligible to Standard Chemotherapy
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Completed
Start date
May 16, 2019
Completion date
March 9, 2024
Enrollment
104 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck